Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valdecoxib (Pharmacia).

Alexander W Gotta1

  • 1State University of New York, Great Neck, Brooklyn 11021-2912, USA. alexandcolleen@prodigy.net

Current Opinion in Investigational Drugs (London, England : 2000)
|May 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

Valdecoxib, a novel cyclooxygenase (COX)-2 inhibitor, received FDA approval in November 2001 for treating arthritis and acute pain. Developed by Pharmacia, it offers improved potency and potential for once-daily dosing compared to other COX-2 inhibitors.

Area of Science:

  • Pharmacology
  • Drug Development
  • Medicinal Chemistry

Background:

  • Valdecoxib is a second-generation cyclooxygenase (COX)-2 inhibitor developed by Pharmacia (formerly Searle), in collaboration with Pfizer and Yamanouchi.
  • It is positioned as a follow-up to celecoxib, targeting arthritis treatment.
  • The development of a prodrug, parecoxib, was initiated due to valdecoxib's poor water solubility.

Purpose of the Study:

  • To detail the development and regulatory status of valdecoxib.
  • To highlight its pharmacological profile and therapeutic potential.
  • To present market predictions and sales forecasts for valdecoxib.

Main Methods:

  • Review of regulatory filings and company announcements regarding valdecoxib.
  • Analysis of published data on valdecoxib's chemical structure and mechanism of action.

Related Experiment Videos

  • Compilation of market analysis reports and sales predictions from financial institutions.

    • Main Results:

    • Pharmacia filed an NDA with the FDA in March 2001 for acute pain, dysmenorrhea, osteoarthritis (OA), and rheumatoid arthritis (RA).
    • Valdecoxib received FDA approval in November 2001.
    • The drug was claimed to possess improved potency and a broader therapeutic range than existing COX-2 inhibitors, with potential for once-daily dosing.

    Conclusions:

    • Valdecoxib represents a significant advancement in the COX-2 inhibitor class.
    • Its development addresses the need for effective arthritis and pain management therapies.
    • Market forecasts indicated substantial commercial potential, with multiple financial institutions predicting significant sales figures in the early 2000s.